| Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline. | |
| | |
MedLine Citation:
|
PMID: 20608914 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Marketing authorization of medicinal products is granted based on results of registration trials. The European Medical Agency (EMA) has issued general and disease state-specific guidelines for the conduct of such trials. In the area of allergic diseases, there are basically two general therapeutic approaches: Drugs that mitigate the symptoms and an approach that is targeted to the root cause of the disease, the allergen-specific immunotherapy (SIT). While the 'Guideline on the Clinical Development of Medicinal Products for the Treatment of Allergic Rhino-Conjunctivitis' (CHMP/EWP/2455/02) and the 'Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Asthma' (CPMP/EWP/2922/01) focuses exclusively on the development of medicinal products to treat allergic symptoms, there was no guideline for SIT in the past. In consequence, the conduct of clinical trials for SIT was widely lacking a standardized approach. This created difficulties when comparing drugs and outcomes and also uncertainty to predict marketing authorization. In 2009, the EMA has issued a new guideline on the clinical development of products for SIT. Despite some white spots in some areas, the new guideline constitutes a breakthrough with regard to guidance, harmonization and transparency in the conduct of clinical trials in SIT. |
| | |
Authors:
|
V Gödicke; F Hundt |
Related Documents
:
|
12774594 - Endoscopic surveillance practice for barrett' s oesophagus in scotland and early experi... 21060744 - A comprehensive model of factors affecting adoption of clinical practice guidelines in ... 11233874 - The management of hypertension in canada: a review of current guidelines, their shortco... 9610044 - Guidelines for evaluation and management of five common podopediatric conditions. 8976504 - Management of behavioral dysfunction: a corporate physician's perspective. 12425374 - Slow decompression of the bladder using an intravenous giving set. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Allergy Volume: 65 ISSN: 1398-9995 ISO Abbreviation: Allergy Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-02 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7804028 Medline TA: Allergy Country: Denmark |
Other Details:
|
Languages: eng Pagination: 1499-505 Citation Subset: IM |
Copyright Information:
|
© 2010 John Wiley & Sons A/S. |
Affiliation:
|
Faculty of Medicine, University of Duisburg-Essen, Essen, Germany. Viola.Goedicke@gmx.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mast cells generated from patients with atopic eczema have enhanced levels of granule mediators and ...
Next Document: Robust expression of CCR3 as a single basophil selection marker in flow cytometry.